The U.S. Food and Drug Administration has approved Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy), a subcutaneous drug used in previously approved adult, solid tumor Opdivo® (nivolumab) indications. A significant number of news sources suggest that Bristol Myers Squibb's (BMY) stock is currently undervalued. The drugmaker has received approval for Opdivo Qvantig for NSCLC T and announced positive topline results from two pivotal Phase 3 trials. Despite market fluctuations, BMY's stock moved -0.55% and -0.89% at various intervals highlighting normal market volatility. BMY employees plan to relay nearly 3,000 miles across the country to raise funds for the V Foundation for Cancer Research. It is worth noting that Bristol-Myers Squibb Company (NYSE:BMY) is favored among institutional investors. The approval of injectable Opdivo reinforces Bristol Myers Squibb's ability to fight off patent cliff concerns. Opdivo's approval is also a sign of growth potential amid strategic acquisitions and revenue increase.
Bristol-Myers Squibb BMY News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Sat, 28 Dec 2024 08:57:33 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor 5
